Special FeaturesLast update October 8, 2019


Search within Ask Paab
Search by Question ID#

We have enhanced the Ask PAAB section to make it more user-friendly due to the growing number of questions. You can now select a category of interest from the drop down menu above to view existing question and answers or you can also do a search for questions that have been submitted to Ask PAAB since the beginning.

Most Recent Questions and Answers

We're developing a pull-up banner and the amount of Fair Balance is not allowing for space for the message. Could we apply the principles allowed for journal ads? Specifically, have medium fair balance on the pull-up banner and direct the reader to a handout adjacent to the panel with the full fair balance?

  • View Answer [+]

Hello, If we want to do a video about the Mode of action of a drug, apart from the PM, what other references can we use?

  • View Answer [+]

In a company sponsored presentation, can a physician talk about off-label for another drug (not the sponsors drug) e.g. "In my practice I use Drug X to treat nausea", but Drug X is not indicated for nausea.

  • View Answer [+]

Is it voluntary to get promotional materials approved and simply acts as a benefit to the product or is it this process mandatory?


Is this "Ask PAAB" still active? We have submitted queries 4-weeks ago and did not see any responses? Could you please provide an update?


Is the PAAB logo required to appear on HCP advertising or patient information approved by PAAB.

  • View Answer [+]

Hi Patrick, I have a question related to providing PAAB training. I remember few years ago you came to our company and you provided training. There have been many changes since then and I was wondering if you are still providing similar training. What is the cost associated with this type of activity? 

  • View Answer [+]

Can you please confirm that use of a drug name along with its pharmacologic classification (eg. 'diuretic') is exempt from PAAB review? The therapeutic classification (eg. 'antihypertensive') would not be included, as this alludes to therapeutic use.


Hi Patrick - I've read the 2019 Client Survey report on the PAAB website. Is there a plan to disseminate this more broadly, and what actions is the PAAB taking with regards to any of the specific survey results? Thank you.

  • View Answer [+]

For advertising a Rx or OTC drug to HCPs, could we add more safety information such as contraindication, warnings...beyond what is in the approved TMA? considering that it is for safety reason e.g. contraindicated in asthma patients (but not stated as such in the TMA). This would be based on a published study or guidelines.

  • View Answer [+]
Deputy Commissioner  

Jennifer Carroll
Senior Reviewer Communications

To view the PAAB
Code of Advertising Acceptance
click here
Pharmaceutical Advertising
Advisory Board
Upcoming meeting

October 16, 2019

Transformation! What it means and how to drive it.

Dinner Meeting
Cocktails: 5:30 p.m.
Dinner: 6:00 p.m.
Panel Discussion: 6:30 p.m.

Click here to register